H2AX and Alzheimer disease: Therefore, we evaluated (Fig. 7 A a1-a9) the presence of the senescence-associated DNA damage marker H2A.X together with the astrocytic marker GFAP in postmortem human brain samples (frontal cortex) from AD patients (Braak V-VI) compared to age-matched individuals without neurological deficits (Braak II).